Seeking Alpha is proud to welcome Cloudforest Capital as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Premium. Click here to find out more »

In this article, I will argue that Boston Scientific Corp. (NYSE:BSX) is a premium Medical Devices company, with its common stock trading at an attractive valuation on the back of a couple of recent setbacks in its Transcatheter Aortic Valve Replacement (TAVR) category. Looking through its current portfolio and pipeline in the medium term, I have confidence that the company will be able to meet its 6-8% organic revenue growth target, with low-mid double digits earnings per share (EPS) growth over the next few years.

READ FULL ARTICLE HERE